.

Make Better Decisions

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Citi
Merck
Dow
Colorcon
Teva
Julphar
Deloitte
Baxter
Mallinckrodt
Harvard Business School

Generated: September 20, 2017

DrugPatentWatch Database Preview

Mallinkrodt Nuclear Company Profile

« Back to Dashboard

What is the competitive landscape for MALLINKRODT NUCLEAR, and when can generic versions of MALLINKRODT NUCLEAR drugs launch?

MALLINKRODT NUCLEAR has eighteen approved drugs.

There is one US patent protecting MALLINKRODT NUCLEAR drugs.

There are twelve patent family members on MALLINKRODT NUCLEAR drugs in eight countries.

Summary for Applicant: Mallinkrodt Nuclear

Patents:1
Tradenames:15
Ingredients:15
NDAs:18
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mallinkrodt Nuclear
THALLOUS CHLORIDE TL 201
thallous chloride tl-201
INJECTABLE;INJECTION018150-001Approved Prior to Jan 1, 1982APRXYesYes► Subscribe► Subscribe► Subscribe
Mallinkrodt Nuclear
TECHNESCAN PYP KIT
technetium tc-99m pyrophosphate kit
INJECTABLE;INJECTION017538-001Approved Prior to Jan 1, 1982APRXNoNo► Subscribe► Subscribe► Subscribe
Mallinkrodt Nuclear
TECHNESCAN
technetium tc-99m oxidronate kit
INJECTABLE;INJECTION018321-001Approved Prior to Jan 1, 1982RXYesYes► Subscribe► Subscribe► Subscribe
Mallinkrodt Nuclear
XENON XE 133
xenon xe-133
GAS;INHALATION018327-002Mar 9, 1982RXNoNo► Subscribe► Subscribe► Subscribe
Mallinkrodt Nuclear
ULTRA-TECHNEKOW FM
technetium tc-99m sodium pertechnetate generator
SOLUTION;INTRAVENOUS017243-003Feb 18, 2014RXYesYes► Subscribe► Subscribe► Subscribe
Mallinkrodt Nuclear
ULTRATAG
technetium tc-99m red blood cell kit
INJECTABLE;INJECTION019981-001Jun 10, 1991RXNoNo► Subscribe► Subscribe► Subscribe
Mallinkrodt Nuclear
GALLIUM CITRATE GA 67
gallium citrate ga-67
INJECTABLE;INJECTION018058-001Approved Prior to Jan 1, 1982BSRXNoNo► Subscribe► Subscribe► Subscribe
Mallinkrodt Nuclear
SODIUM IODIDE I 131
sodium iodide i-131
CAPSULE;ORAL016515-002Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Mallinkrodt Nuclear
SODIUM IODIDE I 123
sodium iodide i-123
CAPSULE;ORAL071909-001Feb 28, 1989AARXNoNo► Subscribe► Subscribe► Subscribe
Mallinkrodt Nuclear
ULTRA-TECHNEKOW FM
technetium tc-99m sodium pertechnetate generator
SOLUTION;INTRAVENOUS017243-002Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Mallinkrodt Nuclear

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Mallinkrodt Nuclear
OCTREOSCAN
indium in-111 pentetreotide kit
INJECTABLE;INJECTION020314-001Jun 2, 1994► Subscribe► Subscribe
Mallinkrodt Nuclear
TECHNESCAN
technetium tc-99m oxidronate kit
INJECTABLE;INJECTION018321-001Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Mallinkrodt Nuclear
TECHNESCAN
technetium tc-99m oxidronate kit
INJECTABLE;INJECTION018321-001Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Mallinkrodt Nuclear
OCTREOSCAN
indium in-111 pentetreotide kit
INJECTABLE;INJECTION020314-001Jun 2, 1994► Subscribe► Subscribe
Mallinkrodt Nuclear
OCTREOSCAN
indium in-111 pentetreotide kit
INJECTABLE;INJECTION020314-001Jun 2, 1994► Subscribe► Subscribe
Mallinkrodt Nuclear
TECHNESCAN MAG3
technetium tc-99m mertiatide kit
INJECTABLE;INJECTION019882-001Jun 15, 1990► Subscribe► Subscribe
Mallinkrodt Nuclear
ULTRATAG
technetium tc-99m red blood cell kit
INJECTABLE;INJECTION019981-001Jun 10, 1991► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Mallinkrodt Nuclear Drugs

Country Document Number Estimated Expiration
United Kingdom9004017► Subscribe
ItalyRM910115► Subscribe
JapanH05124979► Subscribe
Japan3288055► Subscribe
France2658421► Subscribe
United Kingdom9103344► Subscribe
Switzerland683318► Subscribe
Germany4104308► Subscribe
United Kingdom2241167► Subscribe
Belgium1004645► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Mallinkrodt Nuclear Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0076France► SubscribePRODUCT NAME: SIMEPREVIR OU L'UN DE SES SELS, INCLUANT LE SEL DE SODIUM DE SIMEPREVIR; REGISTRATION NO/DATE: EU/1/14/924 20140514
C/GB07/011United Kingdom► SubscribePRODUCT NAME: GADOFOSVESET TRISODIUM; REGISTERED: UK EU/1/05/313/001 20051003; UK EU/1/05/313/002 20051003; UK EU/1/05/313/003 20051003; UK EU/1/05/313/004 20051003; UK EU/1/05/313/005 20051003; UK EU/1/05/313/006 20051003; UK EU/1/05/313/007 20051003; UK EU/1/05/313/008 20051003; UK EU/1/05/313/009 20051003
99C0030Belgium► SubscribePRODUCT NAME: RABEPRAZOLE SODIUM; NAT. REGISTRATION NO/DATE: 5532 IE 1 F 3 19990201; FIRST REGISTRATION: GB 10555/0010 19980508
90062-5Sweden► SubscribePRODUCT NAME: SIMEPREVIR, OR A SALT THEREOF, INCLUDING SIMEPREVIR SODIUM; REG. NO/DATE: EU/1/14/924 20140516
C/GB02/042United Kingdom► SubscribePRODUCT NAME: ERTAPENEM ((1R,5S,6S,8R,2'S,4'S)-2-(2-(3-CARBOXYPHENYLCARBAMOYL)PYRROLIDIN-4-YLTHIO)-6-(1-HYDROXYETHYL)-1-METHYLCARBAPENEM-3-CARBOXYLIC ACID), A PHARMACEUTICALLY ACCEPTABLE SALT OR IN VIVO HYDROLYSABLE ESTER THEREOF, ESPECIALLY AS THE MONOSODIUM SALT ERTA; REGISTERED: UK EU/1/02/216/001 20020418
C0041France► SubscribePRODUCT NAME: ERTAPENEM SODIUM; REGISTRATION NO/DATE: EU/1/02/216/001 20020418
C/GB98/025United Kingdom► SubscribePRODUCT NAME: MONTELUKAST, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREFERABLY MONTELUKAST SODIUM; REGISTERED: FI 12766 19970825; FI 12767 19970825; UK 00025/0357 19980115; UK 00025/0358 19980115
C0055France► SubscribePRODUCT NAME: SULFATE DE SODIUM ANHYDRE, SULFATE DE MAGNESIUM HEPTAHYDRATE, SULFATE DE POTASSIUM; NAT. REGISTRATION NO/DATE: NL41696 20130426; FIRST REGISTRATION: 434323 20130220
595Luxembourg► SubscribePRODUCT NAME: SIMEPREVIR, OU L UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, INCLUANT SIMEPREVIR SODIUM. FIRST REGISTRATION: 20140516
C/GB98/030United Kingdom► SubscribePRODUCT NAME: FOSPHENYTOIN SODIUM (3-HYDROXYMETHYL)-5,5-DIPHENYLHYDANTOIN DISODIUM PHOSPHATE ESTER); REGISTERED: UK 0019/0157 19980204
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Julphar
Cantor Fitzgerald
Cerilliant
Cipla
Boehringer Ingelheim
US Army
Mallinckrodt
AstraZeneca
Merck
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot